ArticleBMJ global health2026
Identifying priority diseases and injuries to promote equality as measured by health-adjusted life expectancy: a population-based study.
Article in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivePromoting healthy lifespan equity is a pivotal challenge in the global wave of population ageing, aiming to enable the majority of people in today's long-lived societies to reach a similar age in good health. This study aims to develop a systematic analytical framework to identify age-specific priority diseases and injuries for intervention, thereby comprehensively improving healthy lifespan equity measured by health-adjusted life expectancy (HALE, the average number of years a person can expect to live in full health).
methodsFirst, we quantify the contribution of reducing the disease burden at each age to changes in overall HALE and healthy lifespan equity. Then, we decompose these contributions into portions attributable to mortality versus disability, ensuring no residual. Finally, we combine these weights with measures of the stability and relative importance of various causes to produce a list of priority causes for intervention across the entire life course.
resultsGlobally, the age-specific leading causes where mortality prevention shall be a priority to achieve healthy lifespan equity are enlisted as follows: neonatal disorders (0 years), malaria (1-4 years), drowning (5-9 years), road injuries (10-24 years), HIV/AIDS (25-44 years) and ischaemic heart disease (45-84 years and over 85 years). The age-specific leading causes of disability in need of prioritisation regarding health lifespan equity are as follows: dietary iron deficiency (0-9 years), headache disorders (10-34 years), low back pain (35-69 years), age-related and other hearing loss (70-84 years) and Alzheimer's disease and other dementias (over 85 years). Notably, the specific ranking and relative importance of these causes varied substantially by region and sex, underscoring the need for context-specific strategies. DISCUSSION: Our comprehensive framework can inform policy-makers of whether resources need to be reallocated to meet the healthy lifespan equity challenges in an ageing era.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.